Germ Cell Tumors
15
1
2
9
Key Insights
Highlights
Success Rate
82% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
13.3%
2 terminated out of 15 trials
81.8%
-4.7% vs benchmark
7%
1 trials in Phase 3/4
44%
4 of 9 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 9 completed trials
Clinical Trials (15)
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
Dose Intensification Study in Refractory Germ Cell Tumors With Relapse and Bad Prognosis
Molecular-Guided Therapy for Childhood Cancer
Paclitaxel, Ifosfamide and Cisplatin (TIP) Versus Bleomycin, Etoposide and Cisplatin (BEP) for Patients With Previously Untreated Intermediate- and Poor-risk Germ Cell Tumors
Auto Transplant for High Risk or Relapsed Solid or CNS Tumors
A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric Refractory Solid Tumors
Aerosolized Azacytidine as Epigenetic Priming for Bintrafusp Alfa-Mediated Immune Checkpoint Blockade in Patients With Unresectable Pulmonary Metastases From Sarcomas, Germ Cell Tumors, or Epithelial Malignancies
Immunohistochemical Evaluation of Protein P16 Expression in Ovarian Germ Cell Tumors.
Pazopanib in Advanced and Cisplatin-resistant Germ Cell Tumors
Simvastatin With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors
Brentuximab Vedotin in Relapsed/Refractory Germ Cell Tumors
Nivolumab in Platinum Recurrent or Refractory Metastatic Germ Cell Tumors
Aprepitant + a 5HT3 + Dexamethasone in Patients With Germ Cell Tumors
Conventional Dose Versus High Dose Sequential Chemotherapy for Poor Prognosis Germ Cell Tumors
Recombinant Human Thrombopoietin in Children Receiving Ifosfamide, Carboplatin, and Etoposide Chemotherapy